Trials / Completed
CompletedNCT02557971
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 315 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a retrospective chart review of patients treated with BOTOX® for idiopathic Overactive Bladder (OAB) as standard of care in clinical practice. The study will determine the rate of post procedural urinary retention requiring catheterization and identify factors that may predict urinary retention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | onabotulinumtoxinA | OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice. |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2016-07-01
- Completion
- 2016-07-01
- First posted
- 2015-09-23
- Last updated
- 2016-09-02
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02557971. Inclusion in this directory is not an endorsement.